[
  {
    "ts": "2025-09-09T19:06:24+00:00",
    "headline": "Amgen Rocatinlimab's Data Shows Potential As Long-Term Therapy For Atopic Dermatitis",
    "summary": "Amgen Inc. (NASDAQ:AMGN) and Kyowa Kirin released preliminary topline results from the ASCEND study evaluating rocatinlimab in adults and adolescents with moderate to severe atopic dermatitis (AD) on Tuesday. The ongoing ASCEND study, which includes approximately 2,600 patients, is designed to evaluate the long-term safety and efficacy of rocatinlimab (150 mg and 300 mg) administered every four or eight weeks in individuals who completed a previous ROCKET program trial (IGNITE, HORIZON, SHUTTLE,",
    "url": "https://finance.yahoo.com/news/amgen-rocatinlimabs-data-shows-potential-190624746.html",
    "source": "Benzinga",
    "provider": "yfinance",
    "raw": {
      "id": "7dc80e20-6fbf-3522-9882-34d555611ccf",
      "content": {
        "id": "7dc80e20-6fbf-3522-9882-34d555611ccf",
        "contentType": "STORY",
        "title": "Amgen Rocatinlimab's Data Shows Potential As Long-Term Therapy For Atopic Dermatitis",
        "description": "",
        "summary": "Amgen Inc. (NASDAQ:AMGN) and Kyowa Kirin released preliminary topline results from the ASCEND study evaluating rocatinlimab in adults and adolescents with moderate to severe atopic dermatitis (AD) on Tuesday. The ongoing ASCEND study, which includes approximately 2,600 patients, is designed to evaluate the long-term safety and efficacy of rocatinlimab (150 mg and 300 mg) administered every four or eight weeks in individuals who completed a previous ROCKET program trial (IGNITE, HORIZON, SHUTTLE,",
        "pubDate": "2025-09-09T19:06:24Z",
        "displayTime": "2025-09-09T19:06:24Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/Benzinga/a2a46140cb18e264f6b93268d4ff7ace",
          "originalWidth": 1000,
          "originalHeight": 563,
          "caption": "Amgen Rocatinlimab's Data Shows Potential As Long-Term Therapy For Atopic Dermatitis",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/gDCV1RUhNnfom7JcLAXxbA--~B/aD01NjM7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/Benzinga/a2a46140cb18e264f6b93268d4ff7ace.cf.webp",
              "width": 1000,
              "height": 563,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/sk6NF.BnzAe6qB6JYP88bw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Benzinga/a2a46140cb18e264f6b93268d4ff7ace.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Benzinga",
          "url": "http://www.benzinga.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/amgen-rocatinlimabs-data-shows-potential-190624746.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/amgen-rocatinlimabs-data-shows-potential-190624746.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "AMGN"
            },
            {
              "symbol": "4151.T"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-09-09T11:22:58+00:00",
    "headline": "Amgen and Kyowa Kirin report preliminary outcomes from AD treatment trial",
    "summary": "ASCEND involves approximately 2,600 subjects and is focused on assessing the therapy’s long-term impact.",
    "url": "https://www.clinicaltrialsarena.com/news/amgen-kyowa-kirin-ad/",
    "source": "Clinical Trials Arena",
    "provider": "yfinance",
    "raw": {
      "id": "810f2a5b-d529-33eb-b593-4cc870b01443",
      "content": {
        "id": "810f2a5b-d529-33eb-b593-4cc870b01443",
        "contentType": "STORY",
        "title": "Amgen and Kyowa Kirin report preliminary outcomes from AD treatment trial",
        "description": "",
        "summary": "ASCEND involves approximately 2,600 subjects and is focused on assessing the therapy’s long-term impact.",
        "pubDate": "2025-09-09T11:22:58Z",
        "displayTime": "2025-09-09T11:22:58Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/clinical_trials_arena_396/fa9e6a6f259d451b12f535ffcc894ac4",
          "originalWidth": 1440,
          "originalHeight": 810,
          "caption": "The therapy is aimed at treating individuals with moderate to severe atopic dermatitis. Credit: Rungkh / Shutterstock.com.",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/t9.dvW.suTMQI7vzx2kRWA--~B/aD04MTA7dz0xNDQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/clinical_trials_arena_396/fa9e6a6f259d451b12f535ffcc894ac4.cf.webp",
              "width": 1440,
              "height": 810,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/sXybtUXKkWKSvyBMUMCo_A--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/clinical_trials_arena_396/fa9e6a6f259d451b12f535ffcc894ac4.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Clinical Trials Arena",
          "url": "https://www.globaldata.com/"
        },
        "canonicalUrl": {
          "url": "https://www.clinicaltrialsarena.com/news/amgen-kyowa-kirin-ad/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/amgen-kyowa-kirin-report-preliminary-112258763.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "AMGN"
            },
            {
              "symbol": "4151.T"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-09-09T04:12:00+00:00",
    "headline": "Amgen and Kyowa Kirin Announce Top-Line Results From Rocatinlimab Phase 3 ASCEND Long-Term Extension Study in Adults With Moderate to Severe Atopic Dermatitis",
    "summary": "THOUSAND OAKS, Calif. and TOKYO, Sept. 09, 2025 (GLOBE NEWSWIRE) -- Amgen (NASDAQ:AMGN) and Kyowa Kirin Co., Ltd. (TSE:4151) today announced preliminary top-line results from the ASCEND study evaluating rocatinlimab, an investigational T-cell rebalancing therapy targeting the OX40 receptor, in adults and adolescents with moderate to severe atopic dermatitis (AD). The ongoing ASCEND study, which includes approximately 2,600 patients, is designed to evaluate the long-term safety and efficacy of ro",
    "url": "https://finance.yahoo.com/news/amgen-kyowa-kirin-announce-top-041200878.html",
    "source": "GlobeNewswire",
    "provider": "yfinance",
    "raw": {
      "id": "ec6c2b82-d482-39a4-beaf-7470f64413d7",
      "content": {
        "id": "ec6c2b82-d482-39a4-beaf-7470f64413d7",
        "contentType": "STORY",
        "title": "Amgen and Kyowa Kirin Announce Top-Line Results From Rocatinlimab Phase 3 ASCEND Long-Term Extension Study in Adults With Moderate to Severe Atopic Dermatitis",
        "description": "",
        "summary": "THOUSAND OAKS, Calif. and TOKYO, Sept. 09, 2025 (GLOBE NEWSWIRE) -- Amgen (NASDAQ:AMGN) and Kyowa Kirin Co., Ltd. (TSE:4151) today announced preliminary top-line results from the ASCEND study evaluating rocatinlimab, an investigational T-cell rebalancing therapy targeting the OX40 receptor, in adults and adolescents with moderate to severe atopic dermatitis (AD). The ongoing ASCEND study, which includes approximately 2,600 patients, is designed to evaluate the long-term safety and efficacy of ro",
        "pubDate": "2025-09-09T04:12:00Z",
        "displayTime": "2025-09-09T04:12:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/globenewswire.com/318e320275c322b5804812b9152c197d",
          "originalWidth": 1165,
          "originalHeight": 224,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/xUyV1.3J81b9rw_djVyGsg--~B/aD0yMjQ7dz0xMTY1O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/318e320275c322b5804812b9152c197d.cf.webp",
              "width": 1165,
              "height": 224,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/DJy_GMupzqzBkpxdFYD5Ww--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/318e320275c322b5804812b9152c197d.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GlobeNewswire",
          "url": "https://www.globenewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/amgen-kyowa-kirin-announce-top-041200878.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/amgen-kyowa-kirin-announce-top-041200878.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "KYKOF"
            },
            {
              "symbol": "KYKOY"
            },
            {
              "symbol": "AMGN"
            },
            {
              "symbol": "4151.T"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-09-09T01:06:00+00:00",
    "headline": "If You'd Invested $10,000 in Amgen Stock (AMGN) 3 Years Ago, Here's How Much You'd Have Today",
    "summary": "You could have done worse -- or much better.",
    "url": "https://www.fool.com/investing/2025/09/08/if-youd-invested-10000-in-amgen-stock-3-years-ago/",
    "source": "Motley Fool",
    "provider": "yfinance",
    "raw": {
      "id": "74fd739d-1f06-332c-8d8e-a85d38895f27",
      "content": {
        "id": "74fd739d-1f06-332c-8d8e-a85d38895f27",
        "contentType": "STORY",
        "title": "If You'd Invested $10,000 in Amgen Stock (AMGN) 3 Years Ago, Here's How Much You'd Have Today",
        "description": "",
        "summary": "You could have done worse -- or much better.",
        "pubDate": "2025-09-09T01:06:00Z",
        "displayTime": "2025-09-09T01:06:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/motleyfool.com/764560c3b7e2bd317f9d536052e2dfb5",
          "originalWidth": 1400,
          "originalHeight": 933,
          "caption": "Someone is looking up, in front of arrows going in different directions on a blackboard.",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/gdkRjsjIzWJ1eskCJk3LOQ--~B/aD05MzM7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/motleyfool.com/764560c3b7e2bd317f9d536052e2dfb5.cf.webp",
              "width": 1400,
              "height": 933,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/H99uje_kogjeFNjaZ1eJvA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/motleyfool.com/764560c3b7e2bd317f9d536052e2dfb5.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Motley Fool",
          "url": "http://www.fool.com/"
        },
        "canonicalUrl": {
          "url": "https://www.fool.com/investing/2025/09/08/if-youd-invested-10000-in-amgen-stock-3-years-ago/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/youd-invested-10-000-amgen-010600576.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "AMGN"
            },
            {
              "symbol": "^SPX"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]